39 related articles for article (PubMed ID: 32286548)
1. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
[TBL] [Abstract][Full Text] [Related]
2. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract][Full Text] [Related]
3. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
[TBL] [Abstract][Full Text] [Related]
4. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
Alshalalfa M; Goglia AG; Swami N; Nguyen B; Hougen HY; Khan A; Kishan AU; Punnen S; Nguyen PL; Mahal BA; Dee EC
Urol Oncol; 2023 May; 41(5):253.e21-253.e26. PubMed ID: 37003878
[TBL] [Abstract][Full Text] [Related]
5. Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer.
Keyvani V; Mollazadeh S; Kheradmand N; Mahmoudian RA; Avan A; Anvari K
Curr Pharm Des; 2023; 29(34):2684-2691. PubMed ID: 37929740
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
Desmée S; Mentré F; Veyrat-Follet C; Sébastien B; Guedj J
BMC Med Res Methodol; 2017 Jul; 17(1):105. PubMed ID: 28716060
[TBL] [Abstract][Full Text] [Related]
7. Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient.
Zacchi F; Carles J; Gonzalez M; Maldonado X; Perez-Lopez R; Semidey ME; Mateo J
Front Oncol; 2024; 14():1331643. PubMed ID: 38525428
[TBL] [Abstract][Full Text] [Related]
8. Low PSA radiographic disease progression on C11-choline PET.
Mahmoud AM; Ahmed ME; Kendi AT; Thorpe M; Johnson GB; Riaz IB; Orme JJ; Kwon ED; Andrews JR; Childs DS
BJUI Compass; 2024 Mar; 5(2):319-324. PubMed ID: 38371200
[TBL] [Abstract][Full Text] [Related]
9. Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.
Venkadakrishnan VB; Yamada Y; Weng K; Idahor O; Beltran H
Mol Cancer Res; 2023 Jun; 21(6):497-510. PubMed ID: 37052520
[TBL] [Abstract][Full Text] [Related]
10. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.
Wang Y; Galante JR; Haroon A; Wan S; Afaq A; Payne H; Bomanji J; Adeleke S; Kasivisvanathan V
Nat Rev Urol; 2022 Aug; 19(8):475-493. PubMed ID: 35789204
[TBL] [Abstract][Full Text] [Related]
11. Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.
Shui X; Xu R; Zhang C; Meng H; Zhao J; Shi C
Lab Invest; 2022 Apr; 102(4):332-340. PubMed ID: 34937865
[TBL] [Abstract][Full Text] [Related]
12. Applications of scaffold-based advanced materials in biomedical sensing.
Sarkhosh-Inanlou R; Shafiei-Irannejad V; Azizi S; Jouyban A; Ezzati-Nazhad Dolatabadi J; Mobed A; Adel B; Soleymani J; Hamblin MR
Trends Analyt Chem; 2021 Oct; 143():116342. PubMed ID: 34602681
[TBL] [Abstract][Full Text] [Related]
13. Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification.
Tian Z; Meng L; Wang X; Wang X; Ma T; Wang M; Zhong Q; Zhang Y; Liu M
Front Oncol; 2021; 11():706236. PubMed ID: 34178701
[TBL] [Abstract][Full Text] [Related]
14. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
Wise DR; Schneider JA; Armenia J; Febles VA; McLaughlin B; Brennan R; Thoren KL; Abida W; Sfanos KS; De Marzo AM; Yegnasubramanian S; Fox JJ; Haas M; Heath H; Kagey MH; Newman W; Sirard CA; Fleisher M; Morris MJ; Chen Y; Larson SM; Haffner MC; Nelson PS; Schultz N; Garabedian MJ; Scher HI; Logan SK; Sawyers CL;
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015525
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer.
Sobhani N; Sirico M; Generali D; Zanconati F; Scaggiante B
World J Clin Oncol; 2020 Jul; 11(7):450-463. PubMed ID: 32821651
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
18. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
